β3-Adrenoreceptor stimulation protects against myocardial infarction injury via eNOS and nNOS activation

Xiaolin Niu1, Lianyou Zhao1, Xue Li1

  • 1Department of Cardiology, Tangdu Hospital, the Fourth Military Medical University, Xi'an, Shaanxi, China.

Plos One
|June 10, 2014
PubMed

Insights

Stimulating the beta-3 adrenergic receptor (β3-AR) protects the heart from myocardial infarction (MI) injury by reducing scar size and preserving cardiac function. This cardioprotective effect involves nitric oxide synthase (NOS) pathways.

Area of Science:

  • Cardiovascular Research
  • Pharmacology
  • Molecular Biology

Background:

  • Beta-3 adrenergic receptor (β3-AR) and nitric oxide synthase (NOS) are emerging modulators of heart function.
  • The cardioprotective role of β3-AR against myocardial infarction (MI) injury remains unclear.

Purpose of the Study:

  • To investigate the effects of β3-AR on MI injury.
  • To elucidate the underlying mechanisms of β3-AR-mediated cardioprotection.

Main Methods:

  • Myocardial infarction (MI) model induced by left anterior descending artery ligation.
  • Administration of β3-AR agonist (BRL37344) or inhibitor (SR59230A).
  • Assessment of cardiac function, fibrosis, scar area, and cardiomyocyte apoptosis via echocardiography, Masson's trichrome stain, and TUNEL assay; protein expression analyzed by Western blot.

Main Results:

  • β3-AR activation significantly reduced fibrosis and scar size post-MI.
  • BRL37344 treatment preserved cardiac function and decreased cardiomyocyte apoptosis.
  • β3-AR stimulation modulated endothelial NOS (eNOS) phosphorylation and increased neuronal NOS (nNOS) expression.

Conclusions:

  • β3-AR stimulation demonstrates significant cardioprotective effects against MI injury.
  • Activation of eNOS and nNOS pathways is potentially associated with the observed cardiac protective effects of β3-AR.

Related Concept Videos

Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.8K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.9K
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
2.2K
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.7K